Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress

被引：7

作者：

Wang, Yaning ^{[1
]}

Chen, Wanqi ^{[1
]}

Shi, Yixin ^{[1
]}

Yan, Chengrui ^{[2
]}

Kong, Ziren ^{[3
]}

Wang, Yuekun ^{[1
]}

Wang, Yu ^{[1
]}

Ma, Wenbin ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China

[2] Peking Univ Int Hosp, Dept Neurosurg, Beijing, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Head & Neck Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

glioblastoma; targeted therapy; phase III trial; phase II trial; overall survival; NEWLY-DIAGNOSED GLIOBLASTOMA; CEREBRAL BLOOD-VOLUME; HEPATOCYTE GROWTH-FACTOR; OPEN-LABEL; RANDOMIZED-TRIAL; DOUBLE-BLIND; PROTEASOME INHIBITORS; MONOCLONAL-ANTIBODY; STANDARD TREATMENT; RADIATION-THERAPY;

D O I：

10.3389/fonc.2021.719623

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The most common primary intracranial tumor is glioma, among which glioblastoma (GBM) has the worst prognosis. Because of the high degree of malignancy of GBM and frequent recurrence after surgery, postoperative therapy, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, is particularly important. A wide variety of targeted drugs have undergone phase III clinical trials for patients with GBM, but these drugs do not work for all patients, and few patients in these trials have prolonged overall survival. In this review, some imposing phase III clinical trials of targeted drugs for glioma are introduced, and some prospective phase II clinical trials that have been completed or are in progress are summarized. In addition, the mechanisms of these drugs are briefly introduced, and deficiencies of these clinical trials are analyzed. This review aims to provide a comprehensive overview of current research on targeted drugs for glioma to clarify future research directions.

引用

页数：13

共 50 条

[31] Quetiapine: Results of four phase II and III clinical trials
King, DJ
[J]. EUROPEAN PSYCHIATRY, 1998, 13 : 15S - 21S
[32] Design issues in phase II/III clinical trials in mesothelioma
Stephens, R.
[J]. LUNG CANCER, 2006, 54 : S7 - S7
[33] Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment
Engohang-Ndong, Jean
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (12) : 1789 - 1800
[34] Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs)
Seruga, B.
Sterling, L.
Wang, L.
Tannock, I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[35] Comparison between phase III randomized clinical trials and their preceeding phase II studies
Lyra-Gonzalez, I.
Espin-Garcia, O.
Krzyzanowska, M. K.
Jang, R. W-J.
Elimova, E.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[36] A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
Cruz Da Silva, Elisabete
Mercier, Marie-Cecile
Etienne-Selloum, Nelly
Dontenwill, Monique
Choulier, Laurence
[J]. CANCERS, 2021, 13 (08)
[37] Analysis of phase II studies on targeted agents and subsequent phase III trials: What are the predictors for success?
Chan, John K.
Ueda, Stefanie M.
Sugiyama, Valerie E.
Stave, Christopher D.
Shin, Jacob Y.
Monk, Bradley J.
Sikic, Branimir I.
Osann, Kathryn
Kapp, Daniel S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1511 - 1518
[38] Evaluation of phase II clinical trials of small molecule targeted inhibitors
Portera, C. C.
Dancey, J. E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[39] Performance status restriction in phase III cancer clinical trials.
Kouzy, Ramez
Jaoude, Joseph Abi
Mainwaring, Walker
Lin, Timothy
Miller, Austin B.
Jethanandani, Amit
Espinoza, Andres F.
Taniguchi, Cullen M.
Ludmir, Ethan B.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[40] CURRENT STATUS OF CLINICAL DEVELOPMENT OF ANTI-TNF BIOSIMILARS: MAIN CHARACTERISTICS AND CURRENT TRENDS OF PHASE III TRIALS
La Noce, A.
Lai, Z.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1002 - 1002

← 1 2 3 4 5 →